On 27 january, the warner pharmaceuticals (688799) issued a communiqué stating that, in recent days, the company had received a letter of termination of the application for registration of medicines approved by the national drug regulatory authority and had agreed to withdraw the company's application for registration of lidocaine gel。
According to the bulletin, the lidoca gel paste is used mainly to relieve the neurological pains of herpes and for the non-breakable skin。
Walner indicated that it had submitted its application for a listing permit for the product to the national drug control authority in march 2025 and was accepted. After careful study and in conjunction with the r & d strategy, the company decided to withdraw its application for registration of the drug on its own initiative. The voluntary withdrawal and termination of the drug registration application will not have a significant impact on the company's current and future production operations and performance。
In fact, prior to the withdrawal of lidoca's gel paste, the warner pharmaceutical plant had withdrawn its registration application for a number of medicines in 2025。
On 18 march 2025, the warner pharmaceuticals company announced that it had recently received a letter of termination of the application for registration of drugs approved by the national drug control authority, agreeing to withdraw the company's application for registration of the acetylic centrifugal acid injection. Injection of acetyl parasicoscilline is used mainly for local inhalation/dipsion or ivs solution treatment for respiratory diseases; for intravenous treatment for acs poisoning。
On 12 october 2025, the warner pharmaceutical plant withdrew its registration application for alore tablets of hydrochloric acid, which was used mainly for the treatment of primary hypertension, arrhythmia, original tremors, etc。
On 29 december 2025, the warner pharmacy also announced the withdrawal of the registration application for silica emulsion, which was used mainly to treat disorders caused by the accumulation of excessive gas in the gastrointestinal tract, such as abdominal swelling, and as a supplementary medicine for abdominal imaging tests。
The reasons for the withdrawal are consistent with those for the withdrawal of lidoca gel。
It is worth noting that three of the four drugs withdrawn by the warnas pharmaceuticals were registered as chemicals in category 4, i. E., lidocaine gel paste, alore tablet with hydrochloric acid and silica emulsion, and acetylene semisicosilicate injections were registered as chemicals in category 3。
According to publicly available information, chemical drugs are classified as imitating drugs listed on the national market, while chemical drugs are described as imitating drugs listed abroad but not on the national market。
The warnas pharmaceuticals plant is a high-technology enterprise that focuses on the development, production and sale of chemical, chemical and chinese preparations. It has the capacity to produce a variety of formulation products, such as tablets, capsules, particles, bulk agents, dry mixers, inhalation solvents, small-volume injections, eye drops, frozen dry powder needles and chemical feedstocks。
After listing, the performance of the warner pharmaceutical plant increased steadily until 2023. In 2024, the net profits earned by the company, attributed to shareholders in the listed company, and the deduction of non-net profits, all decreased by 1. 38 per cent, 22. 24 per cent and 28. 87 per cent respectively。
In the first half of 2025, the company achieved $714 million in operating income, a decrease of 3. 37 per cent over the same period; $7,1115,000 in net profit to the mother, a decrease of 36. 95 per cent over the same period; and $5,915. 3 million in net profit to the non-mother, a decrease of 37. 06 per cent over the same period。
During the reporting period, the decline in net corporate profits was mainly the result of intense market competition and industry policies, declining revenue from formulation products and the gross domestic product (GDP) ratio of raw materials, and the cost of equity incentives. The change in operating income is mainly influenced by the decline in the price of acetylic centrifugal acid solutions in regional alliances。
During the first three quarters of 2025, the warner pharmaceutical plant received 1. 09 billion yuan, an increase of 1. 55 per cent over the same period; the net profit of the returning mother amounted to 207 million yuan, an increase of 30. 75 per cent over the same period, and the net profit of the non-returning mother decreased by 26. 52 per cent, or 9884. 17 million yuan over the same period。
The increase in net profits was mainly the result of the reporting period: (1) the introduction of strategic investors and the restructuring of the board of directors of the shanghai replenishment of medicines and technology ltd., the withdrawal of the company's control, its exclusion from the company's consolidated statements, the residual interest held by the company in a fair value and the recognized return on investment; and (2) the transfer of the investment revenue recognized by hunan tianjin biotech ltd。
According to the warner pharmaceuticals annual report 2025, innovative drug research and development is a long-term strategic choice for the company, which uses a combination of investment in research and development and autonomous research and development, based on its own inadequate original capacity and the long life cycle, high input and high risk of innovative drug development。
The company currently has three pipelines in the field of innovative medicines, one for chinese pharmacological pharmacists, including new chinese pharmacist formulations (one type of innovative drug drying particles) and one type of new pharmacist (substitutes for endangered animal medicines, i. E. Zy series products, carried out on the tianjin rare project platform); the other for methic small molecular pharmacists, to the extent that the medicine is the zg series of products carried out on the project platform; and the third for improved pharmacological pharmacological pharmacists, which are designed in the direction of clinical value discovery, in the direction of permeation, aerosol and nanocline。
Among them, the zg-001 capsule is a new type of antidepressant drug with a completely new structure, developed by shanghai medicines and technology ltd., and is a new type of drug intended for treatment of severe depression (mdsi) associated with suicide intent or behaviour among adults. Zg-001 is conducting iia clinical trials, and companies and clinical centres are actively promoting efforts。
Zg-002, an autonomously developed new type of drug against self-immunological diseases, with a completely new structure, developed by the shanghai medicines and technology company ltd., is a new type of drug intended for treatment of moderate-heavy plaque scabies. The zg-002 project is conducting phase i clinical trials。
On 27 october 2025, the company took part in a bidding exercise for the 11th round of centralized national drug purchases organized by the joint drug procurement office of the state organization. The company's hydrochloride beni tablet was proposed for centralized procurement at a price of $7. 19/boxes, with supply areas including fujian, zhejiang, hubei, ningxia and hainan。
In addition, on 22 october 2025, the company initiated the establishment of hunan fumi probe biotechnic ltd., with a registered capital of $50 million, with a shareholding ratio of 47. 50 per cent, with the main operation being the development of products such as new graphics。
